99% Antineoplastic Rapamycin Powder 99% Purity Rapamycin Sirolimus Rapamycin

China 99% Antineoplastic Rapamycin Powder 99% Purity Rapamycin Sirolimus Rapamycin, Find details about China Rapamycin, Rapamycin Powder from 99% Antineoplastic Rapamycin Powder 99% Purity Rapamycin Sirolimus Rapamycin

Basic Info.

Model NO.

Condavo-Rapamycin

Name

Rapamycin

Product Name

Rapamycin Powder

Appearance

White Powder

Color

White Color

CAS

53123-88-9

Density

1.182

Melting Point

183-185 Oc

Boiling Point

973.017 Oc at 760 Mmhg

Refractive Index

1.55

Flash Point

542.261 Oc

C51h79no13

Assay

99%

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Model NO.

Condavo-Rapamycin

Name

Rapamycin

Product Name

Rapamycin Powder

Appearance

White Powder

Color

White Color

CAS

53123-88-9

Density

1.182

Melting Point

183-185 Oc

Boiling Point

973.017 Oc at 760 Mmhg

Refractive Index

1.55

Flash Point

542.261 Oc

C51h79no13

Assay

99%

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Product Desciption

99% Antineoplastic Rapamycin Powder 99% purity Rapamycin Sirolimus Rapamycin

Product Name	Rapamycin
CAS	53123-88-9
Appearance	White powder
MF	C51H79NO13
Molecular Weight	914.17
Purity	99% min
Storage	Keep in a cool, dry, dark location in a tightly sealed container or cylinder
Shelf Life	24 Months

Rapamycin is a member of the macrolide immunosuppressant family and a FRAP inhibitor.
Rapamycin exhibits binding and inhibitory actions to the FK506 binding protein (FKBP5) proline rotamase via simultaneous binding by FKBP12 and FRAP. FRAP (RAFT1) proteins exhibit homology to PI 4- and PI 3-kinases,which have PI 4-kinase and

autophosphorylating activities.The rapamycin/FKBP complex does not inhibit the FRAP PI 4-kinase activity,but does inhibit FRAP autophosphorylation. Rapamycin is unique in its ability to inhibit lymphokine induced cell proliferation at the G1 and S phase as well as an irreversible cellular arrest at the G1 phase in S. cerevisiae cells. Rapamycin also exhibits selective signal blocking leading to the activation of p70/85 S6 kinase, which is potentially due to the inhibition of FRAP autophosphorylation or protein kinase activity. Angiogenesis inhibition is also exhibited,possibly through the inhibition of the Akt pathway. Rapamycin is an inhibitor of mTOR.

Rapamycin is a triene macrolide antibiotic,which demonstrates anti-fungal,anti-inflammatory,anti-tumor and immunosuppressive properties.
Rapamycin has been shown to block T-cell activation and proliferation,as well as,the activation of p70 S6 kinase and exhibits strong binding to FK506 binding proteins.
Rapamycin also inhibits the activity of the protein,mTOR(mammalian target of rapamycin) which functions in a signaling pathway to promote tumor growth.
Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signaling pathway.

Rapamycin (RAPA) is a novel macrolide immunosuppressant is now often used as a transplanted organ to maintain immunity drugs (especially kidney transplants), to mitigate the immune organ rejection after transplant surgery, but scientists it recently found another purpose: for the treatment of Alzheimer's disease (senile dementia).

Target of rapamycin (mTOR) as an intracellular kinases pathway abnormalities can induce a variety of diseases. As rapamycin mTOR inhibitor targeting, to treat with this pathway is closely related to tumors, including renal cell carcinoma, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer